Comment on "Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Insights from Pivotal and Extension Studies"

Semin Thromb Hemost. 2022 Mar;48(2):251-252. doi: 10.1055/s-0041-1736573. Epub 2021 Nov 8.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Factor IX
  • Factor VIII* / therapeutic use
  • Half-Life
  • Hemophilia A* / drug therapy
  • Humans

Substances

  • Factor VIII
  • Factor IX